OncoMatch/Clinical Trials/NCT06802718
Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia
Is NCT06802718 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Interferon for acute myeloid leukemia.
Treatment: Interferon — This research focuses on a prospective, randomized, controlled trial of "Interferon-alpha as maintenance therapy for favorable-risk acute myeloid leukemia." By fully utilizing prospective, randomized, controlled clinical trial and studying the negative conversion of MRD and the survival of favorable-risk AML patients, it aims to explore the efficacy and safety of Interferon-alpha in the maintenance treatment of favorable-risk AML and identify effective measures to prevent relapse, thereby improving the survival of favorable-risk AML patients. The primary endpoint is the negative conversion of MRD at 6 months. The secondary endpoints include the 2-year cumulative incidence of relapse, 2-year event-free survival (EFS), 2-year overall survival (OS), and safety.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Excluded: CEBPA bZIP intramolecular mutation
AML with normal karyotype and bZIP intramolecular mutations in CEBPA
Allowed: RUNX1 fusion with RUNX1T1, decreased by > 3 log but still detectable
molecular MRD genes (RUNX1:: RUNX1T1, NPM1, and CBFb:: MYH11) decreased by > 3 log, but still detectable
Allowed: NPM1 mutation, decreased by > 3 log but still detectable
molecular MRD genes (RUNX1:: RUNX1T1, NPM1, and CBFb:: MYH11) decreased by > 3 log, but still detectable
Allowed: CBFB fusion with MYH11, decreased by > 3 log but still detectable
molecular MRD genes (RUNX1:: RUNX1T1, NPM1, and CBFb:: MYH11) decreased by > 3 log, but still detectable
Disease stage
Required: Stage CR1
Excluded: Stage CR2 OR GREATER
Achieved CR1 after 1-2 cycles of standard chemotherapy; At the end of consolidation treatment, bone marrow examination confirmed in CR1
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard chemotherapy — induction
Must have received: consolidation chemotherapy (high-dose cytarabine) — consolidation
Lab requirements
Kidney function
creatinine ≤ 1.5 times the upper limit of normal
Liver function
alt and ast ≤ 2.5 times the upper limit of normal, bilirubin ≤ 2 times the upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify